<?xml version='1.0' encoding='utf-8'?>
<document id="23994384"><sentence text="Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience." /><sentence text="Protease inhibitors (PI) with peginterferon/ribavirin have significantly improved SVR rates in HCV G1 patients"><entity charOffset="44-53" id="DDI-PubMed.23994384.s2.e0" text="ribavirin" /></sentence><sentence text=" Their use to treat HCV recurrence after liver transplantation (LT) is a challenge" /><sentence text="" /><sentence text="This cohort study included 37 liver transplant recipients (male, 92%, age 57 ± 11 years), treated with boceprevir (n=18) or telaprevir (n=19)"><entity charOffset="103-113" id="DDI-PubMed.23994384.s5.e0" text="boceprevir" /><entity charOffset="124-134" id="DDI-PubMed.23994384.s5.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23994384.s5.e0" e2="DDI-PubMed.23994384.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s5.e0" e2="DDI-PubMed.23994384.s5.e1" /></sentence><sentence text=" The indication for therapy was HCV recurrence (fibrosis stage ≥F2 (n=31, 83%) or fibrosing cholestatic hepatitis (n=6, 16%)" /><sentence text="" /><sentence text="Eighteen patients were treatment-naive, five were relapsers and fourteen were non-responders to dual therapy after LT" /><sentence text=" Twenty-two patients received cyclosporine and fifteen tacrolimus"><entity charOffset="30-42" id="DDI-PubMed.23994384.s9.e0" text="cyclosporine" /><entity charOffset="55-65" id="DDI-PubMed.23994384.s9.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.23994384.s9.e0" e2="DDI-PubMed.23994384.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s9.e0" e2="DDI-PubMed.23994384.s9.e1" /></sentence><sentence text=" After 12 weeks of PI therapy, a complete virological response was obtained in 89% of patients treated with boceprevir, and 58% with telaprevir (p=0"><entity charOffset="108-118" id="DDI-PubMed.23994384.s10.e0" text="boceprevir" /><entity charOffset="133-143" id="DDI-PubMed.23994384.s10.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23994384.s10.e0" e2="DDI-PubMed.23994384.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s10.e0" e2="DDI-PubMed.23994384.s10.e1" /></sentence><sentence text="06)" /><sentence text=" The end of treatment virological response rate was 72% (13/18) in the boceprevir group and 40% (4/10) in the telaprevir group (p=0"><entity charOffset="71-81" id="DDI-PubMed.23994384.s12.e0" text="boceprevir" /><entity charOffset="110-120" id="DDI-PubMed.23994384.s12.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23994384.s12.e0" e2="DDI-PubMed.23994384.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s12.e0" e2="DDI-PubMed.23994384.s12.e1" /></sentence><sentence text="125)" /><sentence text=" A sustained virological response 12 weeks after treatment discontinuation was observed in 20% (1/5) and 71% (5/7) of patients in the telaprevir and boceprevir groups, respectively (p=0"><entity charOffset="134-144" id="DDI-PubMed.23994384.s14.e0" text="telaprevir" /><entity charOffset="149-159" id="DDI-PubMed.23994384.s14.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.23994384.s14.e0" e2="DDI-PubMed.23994384.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s14.e0" e2="DDI-PubMed.23994384.s14.e1" /></sentence><sentence text="24)" /><sentence text=" Treatment was discontinued in sixteen patients (treatment failures (n=11), adverse events (n=5))" /><sentence text=" Infections occurred in ten patients (27%), with three fatal outcomes (8%)" /><sentence text=" The most common adverse effect was anemia (n=34, 92%), treated with erythropoietin and/or a ribavirin dose reduction; thirteen patients (35%) received red blood cell transfusions"><entity charOffset="93-102" id="DDI-PubMed.23994384.s18.e0" text="ribavirin" /></sentence><sentence text=" The cyclosporine dose was reduced by 1"><entity charOffset="5-17" id="DDI-PubMed.23994384.s19.e0" text="cyclosporine" /></sentence><sentence text="8 ± 1" /><sentence text="1-fold and 3" /><sentence text="4 ± 1" /><sentence text="0-fold with boceprevir and telaprevir, respectively"><entity charOffset="12-22" id="DDI-PubMed.23994384.s23.e0" text="boceprevir" /><entity charOffset="27-37" id="DDI-PubMed.23994384.s23.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23994384.s23.e0" e2="DDI-PubMed.23994384.s23.e0" /><pair ddi="false" e1="DDI-PubMed.23994384.s23.e0" e2="DDI-PubMed.23994384.s23.e1" /></sentence><sentence text=" The tacrolimus dose was reduced by 5"><entity charOffset="5-15" id="DDI-PubMed.23994384.s24.e0" text="tacrolimus" /></sentence><sentence text="2 ± 1" /><sentence text="5-fold with boceprevir and 23"><entity charOffset="12-22" id="DDI-PubMed.23994384.s26.e0" text="boceprevir" /></sentence><sentence text="8±18" /><sentence text="2-fold with telaprevir"><entity charOffset="12-22" id="DDI-PubMed.23994384.s28.e0" text="telaprevir" /></sentence><sentence text="" /><sentence text="Our results suggest that triple therapy is effective in LT recipients, particularly those experiencing a severe recurrence" /><sentence text=" The occurrence of anemia and drug-drug interactions, and the risk of infections require close monitoring" /><sentence text="" /></document>